Navigation Links
Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells
Date:1/24/2008

Appoints U.S. Biotest to Oversee Trials

PRINCETON, N.J., Jan. 24 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that it has signed a clinical services agreement with San Luis Obispo-based, privately held U.S. Biotest, Inc. and will enter Phase II clinical development of DSC127, a novel and rapid wound-healing and scar-reduction product that has a unique mechanism of action potentially linked to the body's own, naturally occurring stem cells. The product has shown promising activity in pre-clinical animal models and has already been tested for safety in a Phase I study in humans.

Through DSC127, Derma Sciences will be able to position itself as a key player in the very large diabetic foot ulcer and scar reduction markets, two rapidly growing and global segments of the wound care market. In the U.S. there are an estimated 2.4 million diabetic foot ulcers and 60,000 diabetes-related amputations each year, which cost healthcare payers more than $10 billion. The market for an FDA-approved scar reduction treatment could reach as high as $4 billion annually in the U.S. alone.

The Phase II study for DSC127, which will be focused on diabetic foot ulcers, is scheduled to begin enrollment in the third quarter of 2008.

"The development of DSC127 is an important milestone for Derma Sciences because it represents an opportunity for us to enter two of the largest and fastest-growing wound care markets in the world today," said Ed Quilty, CEO of Derma Sciences. "Diabetes is a chronic medical issue around the globe and scar reduction, due in large part to the very rapid growth of cosmetic surgeries, is a significant new market for the wound care industry. These are the markets wound care needs to be focused on in the coming months and years and we believe DSC127, particularly due to its potential link to healing through the activation of stem cells
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
2. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
3. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
7. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
8. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... YORK, Sept. 9 New York Blood Center (NYBC), serving ... Island, the Hudson Valley and New Jersey, calls upon our ... and Labor Day holiday weekend have resulted in fewer donations ... B-negative blood for patients in need. Donations from ...
... Polycystic Ovarian Syndrome, known as PCOS, is a silent ... body and increases the risk of serious illness. ... and increases the risk of heart disease, insulin resistance, diabetes ... abnormality in women of child bearing age, affecting 5 to ...
Cached Medicine Technology:Blood Donors Needed as School, Fall Season Returns 2Blood Donors Needed as School, Fall Season Returns 3Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 3
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician ... practices; OB GYN in Melrose Park, IL and ... contains important information about each of the care services and ... forms in English and Spanish. The navigation of the ... the website provide Dr. Furlin’s patients with important information regarding ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... have newly identified 34 unique variations in the human ... sclerosis (ALS). ,The 34 so-called single nucleotide ... to the non-inherited form of the fatal neurodegenerative disease. ... responsible for sporadic ALS, our results seriously narrow the ...
... arteries and giving blood at six-monthly intervals to promote iron reduction ... ,A normal adult has five to six litres of blood ... blood donation. This blood is replaced by the body within 24 ... VA Medical Centre and the Dartmouth Medical School in Vermont looked ...
... for primary ciliary dyskinesia, a rare genetic disease that ... ,According to Thomas Ferkol, M.D., Washington University School of ... of patients with primary ciliary dyskinesia (PCD) have a ... of PCD requires a high index of suspicion, but ...
... such as Tenormin, Inderal and Lopressor should not be a ... a large new review of studies. ,The review, ... that beta-blocker users have a slightly higher risk of death ... such as Norvasc and Cardizem to manage their blood pressure. ...
... determined that low levels of a protein in the blood ... artery disease. ,In a group of men ... Activation, Normal T-cell Expressed, and Secreted), also known as CCL5, ... ,RANTES is a chemokine produced by a variety ...
... breast cancer prevention among women at high risk of the ... found that the breast cancer risk reduction persists long after ... to treat breast cancer and to prevent it among women ... data on tamoxifen for breast cancer prevention comes from the ...
Cached Medicine News:Health News:Human Genetic Code for ALS Identified 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3Health News:Beta-Blockers Should Not Be First Choice for High Blood Pressure 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: